PKA SoftTouch micro-needle technology could solve large-scale vaccination delivery issues to under-served populations worldwide
A future Cleantech Commons tenant, PKA SoftTouch Corp., has launched a public equity crowdfunding campaign for its globally patented micro-needle technology that could play a key role in delivering a vaccine to battle COVID-19.
“During this time of a global pandemic, the need to create fast painless vaccine delivery in pre-measured quantities has never been greater,” CEO Dick Crawford told us.
On March 31, Prime Minister Trudeau called for “made-in-Canada solutions” for desperately needed medical supplies in the face of COVID-19, Crawford points out. During his daily briefing, the prime minister predicted “made-in-Canada supply chains” will emerge to get supplies into the hands of healthcare professionals.
Crawford believes that PKA’s thumb-sized Micro-Needle meets these criteria and has the potential to deliver pain medication and insulin, as well as vaccines, and does so with painless delivery and instant disposability, eliminating fear, needle phobia and disposal issues.
Meanwhile, in the global rush to create a vaccine against the coronavirus, 35 vaccine producers and academic institutions are fast-tracking clinical trials to meet the urgent need, according to a recent report in the Guardian.
PKA’s equity crowdfunding campaign, with an initial short-term funding need of $412,000, will concentrate first on animal clinical trials, followed quickly by human clinical trials. VIEW THE CAMPAIGN HERE!
The campaign is being hosted by the Vancouver-based equity crowdfunding platform, FrontFundr.
The campaign enables small investors to participate in the company’s future growth prospects in a market estimated at $779 billion worldwide for vaccines prior to the onset of COVID-19.
The Micro-Needle works for both humans and animals, and the animal health drug market in Canada alone is on track to reach $1.3 billion by 2024.
“We are confident that once we pass the final clinical trials, pharmaceutical suppliers anxious to quickly retool manufacturing to produce the devices, will step forward to license our technology,” Crawford says.
Clinical trials will be conducted at the University of Guelph, Ontario, and Southlake Regional Health Centre, Newmarket, Ontario.
Contact: Dick Crawford, 705-652-1100, 705-761-9293 email@example.com